{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:31:20Z","timestamp":1783420280334,"version":"3.54.6"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"ProQR Therapeutics, Leiden, the Netherlands"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1038\/s41591-021-01297-7","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T16:02:36Z","timestamp":1617292956000},"page":"785-789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Durable vision improvement after a single treatment with antisense oligonucleotide sepofarsen: a case report"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2018-0905","authenticated-orcid":false,"given":"Artur V.","family":"Cideciyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel G.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen C.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra V.","family":"Garafalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7368-3007","authenticated-orcid":false,"given":"Alejandro J.","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Sumaroka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun K.","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Swider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniz","family":"Girach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"1297_CR1","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1073\/pnas.1913179117","volume":"117","author":"M Hanany","year":"2020","unstructured":"Hanany, M., Rivolta, C. & Sharon, D. Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases. Proc. Natl Acad. Sci. USA 117, 2710\u20132716 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1297_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1086\/507318","volume":"79","author":"AI den Hollander","year":"2006","unstructured":"den Hollander, A. I. et al. Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis. Am. J. Hum. Genet. 79, 556\u2013561 (2006).","journal-title":"Am. J. Hum. Genet."},{"key":"1297_CR3","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/humu.20565","volume":"28","author":"AV Cideciyan","year":"2007","unstructured":"Cideciyan, A. V. et al. Centrosomal-ciliary gene CEP290\/NPHP6 mutations result in blindness with unexpected sparing of photoreceptors and visual brain: implications for therapy of Leber congenital amaurosis. Hum. Mutat. 28, 1074\u20131083 (2007).","journal-title":"Hum. Mutat."},{"key":"1297_CR4","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/hmg\/ddr022","volume":"20","author":"AV Cideciyan","year":"2011","unstructured":"Cideciyan, A. V. et al. Cone photoreceptors are the main targets for gene therapy of NPHP5 (IQCB1) or NPHP6 (CEP290) blindness: generation of an all-cone Nphp6 hypomorph mouse that mimics the human retinal ciliopathy. Hum. Mol. Genet. 20, 1411\u20131423 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"1297_CR5","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1167\/iovs.17-21560","volume":"58","author":"SG Jacobson","year":"2017","unstructured":"Jacobson, S. G. et al. Outcome measures for clinical trials of Leber congenital amaurosis caused by the intronic mutation in the CEP290 gene. Invest. Ophthalmol. Vis. Sci. 58, 2609\u20132622 (2017).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1297_CR6","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1167\/iovs.19-26672","volume":"60","author":"AV Cideciyan","year":"2019","unstructured":"Cideciyan, A. V. & Jacobson, S. G. Leber congenital amaurosis (LCA): potential for improvement of vision. Invest. Ophthalmol. Vis. Sci. 60, 1680\u20131695 (2019).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1297_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41591-018-0295-0","volume":"25","author":"AV Cideciyan","year":"2019","unstructured":"Cideciyan, A. V. et al. Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect. Nat. Med. 25, 225\u2013228 (2019).","journal-title":"Nat. Med."},{"key":"1297_CR8","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1167\/iovs.19-27156","volume":"60","author":"A Sumaroka","year":"2019","unstructured":"Sumaroka, A. et al. Treatment potential for macular cone vision in Leber congenital amaurosis due to CEP290 or NPHP5 mutations: predictions from artificial intelligence. Invest. Ophthalmol. Vis. Sci. 60, 2551\u20132562 (2019).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1297_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.visres.2020.01.006","volume":"168","author":"AK Krishnan","year":"2020","unstructured":"Krishnan, A. K. et al. Transient pupillary light reflex in CEP290- or NPHP5-associated Leber congenital amaurosis: latency as a potential outcome measure of cone function. Vis. Res. 168, 53\u201363 (2020).","journal-title":"Vis. Res."},{"key":"1297_CR10","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.omtn.2018.07.010","volume":"12","author":"K Dulla","year":"2018","unstructured":"Dulla, K. et al. Splice-modulating oligonucleotide QR-110 restores CEP290 mRNA and function in human c.2991+1655A>G LCA10 models. Mol. Ther. Nucleic Acids 12, 730\u2013740 (2018).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1297_CR11","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.ophtha.2009.09.056","volume":"117","author":"S Walia","year":"2010","unstructured":"Walia, S. et al. Visual acuity in patients with Leber\u2019s congenital amaurosis and early childhood-onset retinitis pigmentosa. Ophthalmology 117, 1190\u20131198 (2010).","journal-title":"Ophthalmology"},{"key":"1297_CR12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.molmed.2018.06.006","volume":"24","author":"I Trapani","year":"2018","unstructured":"Trapani, I. & Auricchio, A. Seeing the light after 25 years of retinal gene therapy. Trends Mol. Med. 24, 669\u2013681 (2018).","journal-title":"Trends Mol. Med."},{"key":"1297_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","volume":"25","author":"ML Maeder","year":"2019","unstructured":"Maeder, M. L. et al. Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat. Med. 25, 229\u2013233 (2019).","journal-title":"Nat. Med."},{"key":"1297_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","volume":"578","author":"JA Doudna","year":"2020","unstructured":"Doudna, J. A. The promise and challenge of therapeutic genome editing. Nature 578, 229\u2013236 (2020).","journal-title":"Nature"},{"key":"1297_CR15","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","volume":"94","author":"KM Schoch","year":"2017","unstructured":"Schoch, K. M. & Miller, T. M. Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases. Neuron 94, 1056\u20131070 (2017).","journal-title":"Neuron"},{"key":"1297_CR16","first-page":"2646","volume":"42","author":"SP Henry","year":"2001","unstructured":"Henry, S. P. et al. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication. Invest. Ophthalmol. Vis. Sci. 42, 2646\u20132651 (2001).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1297_CR17","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1364\/BOE.7.004554","volume":"7","author":"OP Kocaoglu","year":"2016","unstructured":"Kocaoglu, O. P. et al. Photoreceptor disc shedding in the living human eye. Biomed. Opt. Express 7, 4554\u20134568 (2016).","journal-title":"Biomed. Opt. Express"},{"key":"1297_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.preteyeres.2018.12.004","volume":"71","author":"W Baehr","year":"2019","unstructured":"Baehr, W. et al. Insights into photoreceptor ciliogenesis revealed by animal models. Prog. Retin Eye Res. 71, 26\u201356 (2019).","journal-title":"Prog. Retin Eye Res."},{"key":"1297_CR19","doi-asserted-by":"publisher","unstructured":"Potter V. L., Moye A. R., Robichaux M. A., Wensel T. G. Superresolution microscopy reveals photoreceptor-specific subciliary location and function of Cep290. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.10.28.357806 (2020).","DOI":"10.1101\/2020.10.28.357806"},{"key":"1297_CR20","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1167\/iovs.09-5074","volume":"51","author":"KW Littink","year":"2010","unstructured":"Littink, K. W. et al. A novel nonsense mutation in CEP290 induces exon skipping and leads to a relatively mild retinal phenotype. Invest. Ophthalmol. Vis. Sci. 51, 3646\u20133652 (2010).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1297_CR21","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1167\/iovs.09-3734","volume":"51","author":"S Pasadhika","year":"2010","unstructured":"Pasadhika, S. et al. Differential macular morphology in patients with RPE65-, CEP290-, GUCY2D-, and AIPL1-related Leber congenital amaurosis. Invest. Ophthalmol. Vis. Sci. 51, 2608\u20132614 (2010).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1297_CR22","first-page":"412","volume":"18","author":"S Yzer","year":"2012","unstructured":"Yzer, S. et al. Ocular and extra-ocular features of patients with Leber congenital amaurosis and mutations in CEP290. Mol. Vis. 18, 412\u2013425 (2012).","journal-title":"Mol. Vis."},{"key":"1297_CR23","doi-asserted-by":"publisher","first-page":"7130","DOI":"10.1167\/iovs.15-17467","volume":"56","author":"FT Collison","year":"2015","unstructured":"Collison, F. T., Park, J. C., Fishman, G. A., McAnany, J. J. & Stone, E. M. Full-field pupillary light responses, luminance thresholds, and light discomfort thresholds in CEP290 Leber congenital amaurosis patients. Invest. Ophthalmol. Vis. Sci. 56, 7130\u20137136 (2015).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1297_CR24","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.ophtha.2017.12.013","volume":"125","author":"L Sheck","year":"2018","unstructured":"Sheck, L. et al. Leber congenital amaurosis associated with mutations in CEP290, clinical phenotype, and natural history in preparation for trials of novel therapies. Ophthalmology 125, 894\u2013903 (2018).","journal-title":"Ophthalmology"},{"key":"1297_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ajo.2019.11.012","volume":"211","author":"B Feldhaus","year":"2020","unstructured":"Feldhaus, B. et al. CEP290 mutation spectrum and delineation of the associated phenotype in a large German cohort: a monocentric study. Am. J. Ophthalmol. 211, 142\u2013150 (2020).","journal-title":"Am. J. Ophthalmol."},{"key":"1297_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0002-9394(82)90197-0","volume":"94","author":"FL Ferris 3rd","year":"1982","unstructured":"Ferris, F. L. 3rd, Kassoff, A., Bresnick, G. H. & Bailey, I. New visual acuity charts for clinical research. Am. J. Ophthalmol. 94, 91\u201396 (1982).","journal-title":"Am. J. Ophthalmol."},{"key":"1297_CR27","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.ophtha.2008.03.009","volume":"115","author":"JS Sunness","year":"2008","unstructured":"Sunness, J. S. et al. Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration. Ophthalmology 115, 1480\u20131488 (2008).","journal-title":"Ophthalmology"},{"key":"1297_CR28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.exer.2004.09.008","volume":"80","author":"AJ Roman","year":"2005","unstructured":"Roman, A. J. et al. Quantifying rod photoreceptor-mediated vision in retinal degenerations: dark-adapted thresholds as outcome measures. Exp. Eye Res. 80, 259\u2013272 (2005).","journal-title":"Exp. Eye Res."},{"key":"1297_CR29","doi-asserted-by":"publisher","first-page":"N51","DOI":"10.1088\/0967-3334\/28\/8\/N02","volume":"28","author":"AJ Roman","year":"2007","unstructured":"Roman, A. J., Cideciyan, A. V., Aleman, T. S. & Jacobson, S. G. Full-field stimulus testing (FST) to quantify visual perception in severely blind candidates for treatment trials. Physiol. Meas. 28, N51\u2013N56 (2007).","journal-title":"Physiol. Meas."},{"key":"1297_CR30","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1093\/hmg\/dds421","volume":"22","author":"SG Jacobson","year":"2013","unstructured":"Jacobson, S. G. et al. Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone\u2013photoreceptor vision correlates with biochemical properties of the mutants. Hum. Mol. Genet. 22, 168\u2013183 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"1297_CR31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10633-009-9204-7","volume":"119","author":"M Klein","year":"2009","unstructured":"Klein, M. & Birch, D. G. Psychophysical assessment of low visual function in patients with retinal degenerative diseases (RDDs) with the Diagnosys full-field stimulus threshold (D-FST). Doc. Ophthalmol. 119, 217\u2013224 (2009).","journal-title":"Doc. Ophthalmol."},{"key":"1297_CR32","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1097\/IAE.0000000000000144","volume":"34","author":"FT Collison","year":"2014","unstructured":"Collison, F. T., Fishman, G. A., McAnany, J. J., Zernant, J. & Allikmets, R. Psychophysical measurement of rod and cone thresholds in Stargardt disease with full-field stimuli. Retina 34, 1888\u20131895 (2014).","journal-title":"Retina"},{"key":"1297_CR33","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1089\/hum.2013.153","volume":"24","author":"AV Cideciyan","year":"2013","unstructured":"Cideciyan, A. V. et al. Human cone visual pigment deletions spare sufficient photoreceptors to warrant gene therapy. Hum. Gene Ther. 24, 993\u20131006 (2013).","journal-title":"Hum. Gene Ther."},{"key":"1297_CR34","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1364\/JOSAA.24.001457","volume":"24","author":"AV Cideciyan","year":"2007","unstructured":"Cideciyan, A. V. et al. Reduced-illuminance autofluorescence imaging in ABCA4-associated retinal degenerations. J. Opt. Soc. Am. A 24, 1457\u20131467 (2007).","journal-title":"J. Opt. Soc. Am. A"},{"key":"1297_CR35","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1167\/iovs.07-1505","volume":"49","author":"W Herrera","year":"2008","unstructured":"Herrera, W. et al. Retinal disease in Usher syndrome III caused by mutations in the clarin-1 gene. Invest. Ophthalmol. Vis. Sci. 49, 2651\u20132660 (2008).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1297_CR36","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1167\/iovs.09-3471","volume":"50","author":"D Gibbs","year":"2009","unstructured":"Gibbs, D., Cideciyan, A. V., Jacobson, S. G. & Williams, D. S. Retinal pigment epithelium defects in humans and mice with mutations in MYO7A: imaging melanosome-specific autofluorescence. Invest. Ophthalmol. Vis. Sci. 50, 4386\u20134393 (2009).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1297_CR37","first-page":"59","volume":"49","author":"B Saletu","year":"1988","unstructured":"Saletu, B. & Gr\u00fcnberger, J. Drug profiling by computed electroencephalography and brain maps, with special consideration of sertraline and its psychometric effects. J. Clin. Psychiatry 49, 59\u201371 (1988).","journal-title":"J. Clin. Psychiatry"},{"key":"1297_CR38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0167-8760(02)00122-8","volume":"47","author":"E Granholm","year":"2003","unstructured":"Granholm, E. et al. Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer\u2019s and Parkinson\u2019s disease. Int. J. Psychophysiol. 47, 95\u2013115 (2003).","journal-title":"Int. J. Psychophysiol."},{"key":"1297_CR39","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1167\/iovs.14-15895","volume":"56","author":"AV Cideciyan","year":"2014","unstructured":"Cideciyan, A. V. et al. Pseudo-fovea formation after gene therapy for RPE65-LCA. Invest. Ophthalmol. Vis. Sci. 56, 526\u2013537 (2014).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1297_CR40","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1167\/iovs.11-8415","volume":"53","author":"AV Cideciyan","year":"2012","unstructured":"Cideciyan, A. V. et al. Macular function in macular degenerations: repeatability of microperimetry as a potential outcome measure for ABCA4-associated retinopathy trials. Invest. Ophthalmol. Vis. Sci. 53, 841\u2013852 (2012).","journal-title":"Invest. Ophthalmol. Vis. Sci."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-021-01297-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-021-01297-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-021-01297-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:04:28Z","timestamp":1684620268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01297-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1297"],"URL":"https:\/\/doi.org\/10.1038\/s41591-021-01297-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"assertion":[{"value":"13 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.R.S. and A.G. are employees of ProQR Therapeutics. All other authors have no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}